Abstract: Understanding and improving the effects of combined drug treatments in metastatic colorectal Cancer (mCRC) is a multidisci-plinary and multiscale problem, that can benet from a systems biology approach. Although a quite limited number of active drugs have been approved for clinical applications, a variety of combined delivery regimen options are actually used in the clinic, so that choosing between them, or designing new ones, is not an obvious task, which calls for some rationalization based on physiological principles. We propose some physiologically based molecular pharmacokinetics-pharmacodynamics models for the main cytotoxic drugs used in the clinic and call for others describing more recently used agents, such as associated...
More therapeutic options are now available than ever before for patients with metastatic colorectal ...
(1) Background: colorectal cancer (CRC) is one of the deadliest causes of death by cancer worldwide....
In this paper, we introduce a model for drug delivery optimisation in a chronotherapeu-tics framewor...
International audienceUnderstanding and improving the effects of combined drug treatments in metastat...
The therapeutic landscape of metastatic colorectal cancer (mCRC) has changed substantially with the ...
Optimizing cancer pharmacotherapeutics using mathematical modeling and a systems biology approach Me...
Current colorectal cancer (CRC) treatment guidelines are primarily based on clinical features, such ...
This review aims at presenting a synoptic, if not exhaustive, point of view on some of the problems ...
Colorectal cancer will kill approximately 50,000 people in the United States this year. Current trea...
This review aims at presenting a synoptic, if not exhaustive, point of view on some of the problems ...
Colorectal cancer (CRC) is the third most common cancer in the UK, with over 37,500 people being dia...
A mathematical model for time development of metastases and their distribution in size and carrying ...
(1) Background: colorectal cancer (CRC) is one of the deadliest causes of death by cancer worldwide....
One of the most common and deadly cancers in the world, colorectal cancer (CRC) caused around 881,00...
International audienceThe aim here was to explore the potential of pharmacokinetic (PK)/pharmacodyna...
More therapeutic options are now available than ever before for patients with metastatic colorectal ...
(1) Background: colorectal cancer (CRC) is one of the deadliest causes of death by cancer worldwide....
In this paper, we introduce a model for drug delivery optimisation in a chronotherapeu-tics framewor...
International audienceUnderstanding and improving the effects of combined drug treatments in metastat...
The therapeutic landscape of metastatic colorectal cancer (mCRC) has changed substantially with the ...
Optimizing cancer pharmacotherapeutics using mathematical modeling and a systems biology approach Me...
Current colorectal cancer (CRC) treatment guidelines are primarily based on clinical features, such ...
This review aims at presenting a synoptic, if not exhaustive, point of view on some of the problems ...
Colorectal cancer will kill approximately 50,000 people in the United States this year. Current trea...
This review aims at presenting a synoptic, if not exhaustive, point of view on some of the problems ...
Colorectal cancer (CRC) is the third most common cancer in the UK, with over 37,500 people being dia...
A mathematical model for time development of metastases and their distribution in size and carrying ...
(1) Background: colorectal cancer (CRC) is one of the deadliest causes of death by cancer worldwide....
One of the most common and deadly cancers in the world, colorectal cancer (CRC) caused around 881,00...
International audienceThe aim here was to explore the potential of pharmacokinetic (PK)/pharmacodyna...
More therapeutic options are now available than ever before for patients with metastatic colorectal ...
(1) Background: colorectal cancer (CRC) is one of the deadliest causes of death by cancer worldwide....
In this paper, we introduce a model for drug delivery optimisation in a chronotherapeu-tics framewor...